- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Amgen Inc
+ Add to WatchlistAMGN:US
106.0700 USD 1.8300 1.76%
Share
As of 12:45:25 ET on 05/22/2013.
More on AMGN
News for Amgen Inc (AMGN)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Tennis With Evert, Baseball With Microsoft: D.C. Scene
- Manatt, Jones Day, Howrey, Ropes & Gray: Business of Law
- Monsanto, Nike, Deutsche Boerse: Intellectual Property
- Monsanto Wins Seed Case as High Court Backs Patent Rights
- Amgen Drugs May Boost Survival During a Nuclear Attack
- Merck Cuts Profit Forecast as Buyback Boosted $15 Billion
- Amgen Falls After Revenue Growth Misses Estimates
- Biotechnology Draws Record Profit as Research Money Slows
- Chili Peppers Seen Helping 36 Million Migraine Sufferers
- Bayer, Amgen Face Price Cuts as German Panel Expands Drug Review
- Hikma to Keep Injectable-Drug Unit After Completing Review
- Patenting Genes, Trolls, Domains: Intellectual Property
- Wachtell, WilmerHale, Cravath, Skadden: Business of Law
- High Court Justices Seek Compromise in Gene-Patent Case
- Genes, Fake Wine, Martha Stewart: Intellectual Property
- Amgen To Present At The UBS Global Life Sciences Conference Published May 16, 2013
- Amgen and Novartis Join Atlas Venture Fund IX As Corporate Strategic Partners Published May 16, 2013
- The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals Published May 16, 2013
- New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer Published May 15, 2013
- Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting Published May 15, 2013
- Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China Published May 09, 2013
- Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Published May 07, 2013
- Transgenomic Signs Collaboration Agreement with Amgen for Development of CE-IVD CRC RAScan™ Mutation Detection Tests for Published May 06, 2013
- Four Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California Published May 01, 2013
- FDA POSTS REVIEW OF AMGEN, SANOFI DRUGS AS RADIATION TREATMENTS Published May 01, 2013
- Amgen welcomes European Commission report on EU biosimilars uptake Published Apr 30, 2013
- Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Published Apr 24, 2013
- The Zacks Analyst Blog Highlights: Amgen, Freeport-McMoRan Copper & Gold, Plains Exploration & Production, McMoRan Exploration Published Apr 23, 2013
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail Updated 1 hour ago
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says Updated 1 hour ago
- Addex Rises on Positive Rodent Experiment Results: Zurich Mover
- Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting
- Teva Bets on Reformulating Old Drugs as Investors Say ‘Show Me’
- Royalty Pharma Raises Elan Bid to $12.50 a Share in Cash
- U.K. to Pilot Illumina Genetic Test for Breast, Ovarian Cancer
- Largest Weekly Option Sentiment Changes for S&P 500 Companies
- SAC Digs In as Deadline Nears for U.S. Insider Cases
- Japan Biotech Firms Jump as Abenomics Cash Spurs Speculation
- Puma Biotech Gains After Rival Drug Data Show No Threat
- Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine
- Billionaire Frost Props Up Prolor Bid With Stock Buys
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Gene-Testing Dispute Focuses on How Much a Patient Should Know
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page